GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (CHIX:PRTCl) » Definitions » Short Interest

PureTech Health (CHIX:PRTCL) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is PureTech Health Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of PureTech Health's Short Interest

For the Biotechnology subindustry, PureTech Health's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PureTech Health's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's Short Interest distribution charts can be found below:

* The bar in red indicates where PureTech Health's Short Interest falls into.


;
;

PureTech Health Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (CHIX:PRTCl) » Definitions » Short Interest
Comparable Companies
LSE:OXB LSE:FARN LSE:IBT LSE:4BB LSE:BVXP LSE:HVO LSE:AVCT LSE:SCLP LSE:SBTX LSE:OBI VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
PRTC:USA PTCHF:USA PRTC:UK 0VQ:Germany
Address
6 Tide Street, Suite 400, Boston, MA, USA, 02210
Website
https://www.puretechhealth.com
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

PureTech Health Headlines

No Headlines